Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.

The star of Gilead's fourth-quarter call was its Hep C drug GS-7977, helping investor overlook lower-than-expected 2012 guidance.

The market's insatiable demand for Hep C speculative trades was met Tuesday by a little-known Israeli drug maker.

Tiffany has more bling and old problems haunt the maker of Blackberry.

A group of Wall Street investors are bullish on Hep C drug stocks, including the belief that Idenix Pharma is the next takeover target.

Markets are treading cautiously into the start of today's crucial trading session ahead of a key Fed rate decision and the start of mega cap tech earnings after the closing bell.

The two billionaires have just sung the praises of the new hit TV series, which is an adaptation of a videogame.

Advanced Micro Devices reported earnings strong enough to trigger a post-report rally. Now AMD stock is trying for a major breakout.

"If you’ve been wondering whether or not Peloton can make an epic comeback, this quarter's results show the changes we’re making are working," said CEO Barry McCarthy